In a webcast addressed to shareholders, CLINUVEL’s Managing Director, Dr Philippe Wolgen, covers CLINUVEL’s market position, financial management and the Group’s unfolding growth and expansion strategy.
- Home
- People
- CLINUVEL news
CUV151 DNA Repair Study Update
CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, discusses the recent results from the CUV151 study, looking at whether afamelanotide can reduce and repair photodamage (skin damage induced by ultraviolet radiation) in healthy volunteers.CLINUVEL newsDr Pilar Bilbao — CLINUVEL’s DNA Repair Program
CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, discusses the global relevance of the Company’s DNA Repair program, as well as the significance of the recently released first results from the CUV151 study in healthy volunteers.CLINUVEL newsCLINUVEL: developing innovative treatments for stroke patients
CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, provides an overview of results from the first clinical study of CLINUVEL’s drug afamelanotide in arterial ischaemic stroke (AIS) patients, then discusses the impact for patients’ lives and gives an update on the next steps in the clinical program for AIS.CLINUVEL newsNasdaq TradeTalks Interview
CLINUVEL’s Managing Director, Dr Philippe Wolgen, speaks with Jill Malandrino on Nasdaq TradeTalks, 26 October 2021.
- R&D
- CLINUVEL news
Sydney Capital Markets Briefing: Vitiligo
Dr Dennis Wright, CLINUVEL’s Chief Scientific Officer, explains the rationale behind the clinical endpoints of the Company’s CUV105 vitiligo study, as well as the program’s pathway to market.CLINUVEL newsSydney Capital Markets Briefing: R&D pipeline
Dr Dennis Wright, CLINUVEL’s Chief Scientific Officer, provided insights into the Company’s R&D pipeline at the Capital Markets Briefing that took place in Sydney in May.CLINUVEL newsCUV151 DNA Repair Study Update
CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, discusses the recent results from the CUV151 study, looking at whether afamelanotide can reduce and repair photodamage (skin damage induced by ultraviolet radiation) in healthy volunteers.CLINUVEL newsDr Pilar Bilbao — CLINUVEL’s DNA Repair Program
CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, discusses the global relevance of the Company’s DNA Repair program, as well as the significance of the recently released first results from the CUV151 study in healthy volunteers.
- Publications
- Publications
The Weekend Effect – A Worrying Truth or Myth?
Reduced staff over the weekends is the norm for many retail shops, but what about in healthcare? A number of reviews have...PublicationsIs skin cancer in your job description?
Those of us working from offices, or our own homes, aren’t expecting danger pay. However, what about those who have jobs that heighten the risk of getting skin...PublicationsTomatoes and carrots… photoprotection from within?
Most of us have been spun a myth that eating our crusts will make our hair shiny, and that we should...PublicationsHas COVID-19 Had an Effect on Sun Protection Behaviours?
Quarantine fatigue amongst the general public may result in a higher incidence rate of sunburn, according to a recent analysis of...
- Finance & investing
- CLINUVEL news
Managing Director’s End of Year Message 2024
CLINUVEL’s Managing Director (MD), Dr Philippe Wolgen, addresses questions received from shareholders and what lies ahead.CLINUVEL newsCLINUVEL 2024 Annual General Meeting — recording
CLINUVEL’s 2024 Annual General Meeting was held on 16 October 2024. Watch the recording from the event.CLINUVEL newsCLINUVEL FY2024 Financial Results Webinar
CLINUVEL held a webinar to discuss the Company’s financial results for the year ended 30 June 2024 and its diversification plans for long-term sustainability.CLINUVEL newsSydney Capital Markets Briefing: Commercial Update
CLINUVEL’s Director of Global Operations, Lachlan Hay, presented at the Capital Markets Briefing that took place in Sydney earlier this month.